查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1405789

粗针穿刺切片市场规模、份额、趋势分析报告：按技术、最终用途、地区、细分市场预测，2023-2030 年

Breast Cancer Core Needle Biopsy Market Size, Share & Trends Analysis Report By Technology, By End-use (Hospitals & Diagnostic Laboratories, Academic & Research Institutes), By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10个工作天内

价格

乳癌粗针穿刺切片市场成长与趋势：

Grand View Research, Inc.的最新报告显示，到2030年，全球粗针穿刺切片市场预计将达到11.5亿美元。

预计2023年至2030年该市场将以4.9%的复合年增长率成长。推动市场成长的主要因素是乳癌盛行率的增加、定期乳房X光检查的广泛普及、个人意识的提高以及在该领域进行的广泛研究。这些因素共同促进了粗针穿刺切片的需求和采用不断增加，为未来几年的显着增长铺平了道路。

此外，影像和切片检查技术的不断进步也促进了该行业的扩张。人们越来越认识到早期检测和诊断在改善患者预后方面发挥的重要作用。与传统的开放性手术切片检查相比，粗针穿刺切片具有明显的优势，包括侵入性更小、恢復时间更快和成本效益高。

随着早期检测和诊断的需求持续上升，粗针穿刺切片市场预计将显着成长。该领域最新的创新研究例子包括西班牙 IMIM（德尔马医院医学研究所）研究人员于 2022 年在《欧洲放射学》上发表的一项研究，该研究使用 MRI 技术来可视化病变，其中包括使用造影增强乳腺X 光检查引导乳房切片。

COVID-19大流行乳癌粗针穿刺切片市场带来了挑战，也带来了新的机会。不必要的程序延误导致诊断率降低并减少了对粗针穿刺切片的需求。然而，疫情凸显了早期检测的重要性，迫使医疗保健提供者优先考虑筛检和切片检查，导致需求回升。

粗针穿刺切片市场报告亮点

  • 从技术角度来看，超音波乳房切片领域由于其在疾病诊断方面优于其他切片检查技术，将在 2022 年占据市场主导地位。此外，技术进步的不断进步预计也将加速该行业的成长。
  • 按最终用途划分，医院和诊断实验室产业在 2022 年占据最大的市场占有率。这是由于医院越来越多地采用乳癌切片检查设备以及对新诊断技术的需求不断增加。
  • 由于其高度发展的医疗基础设施和技术先进的公司的存在，北美在 2022 年将在市场中占据强大的区域地位。

目录

第一章调查方法和范围

第 2 章执行摘要

第三章市场变数、趋势和范围

  • 市场区隔和范围
  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场趋势及展望
  • 市场驱动因素
    • 乳癌发生率增加
    • 影像和切片检查技术的进步
    • 人们对微创手术的兴趣日益浓厚
  • 市场约束
    • 粗针穿刺切片手术成本高
    • 专业知识和培训有限
  • 产业分析工具
    • 波特五力分析
    • PESTEL分析
    • COVID-19感染疾病的影响分析

第四章科技业务分析

  • 粗针穿刺切片市场：技术变化分析
  • 基于 MRI 的乳房切片
    • 基于 MRI 的乳房切片市场，2018-2030 年
  • 超音波乳房切片
    • 超音波乳房切片市场，2018-2030
  • 基于乳房X光检查（立体定位）的乳房切片
    • 乳房X光摄影底座
  • 基于 CT 的乳房切片
    • 基于 CT 的乳房切片市场，2018-2030 年
  • 其他基于图像的乳房切片
    • 其他基于影像的乳房切片市场，2018-2030

第五章 最终用途业务分析

  • 粗针穿刺切片市场：最终用途变化分析
  • 医院/检测机构
    • 医院和实验室市场，2018-2030
  • 製药和生物技术公司
    • 製药和生物技术公司、市场，2018-2030
  • 学术/研究机构
    • 学术和研究机构市场，2018-2030

第六章 区域业务分析

  • 2022年及2030年粗针穿刺切片市场占有率（按地区）
  • 北美洲
    • SWOT分析
    • 北美粗针穿刺切片，2018-2030
    • 美国
    • 加拿大
  • 欧洲
    • SWOT分析
    • 欧洲乳癌粗针穿刺切片市场，2018-2030
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • SWOT分析
    • 亚太地区粗针穿刺切片，2018-2030
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 泰国
    • 韩国
  • 拉丁美洲
    • SWOT分析
    • 拉丁美洲粗针穿刺切片，2018-2030 年
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东/非洲
    • SWOT分析
    • 中东和非洲粗针穿刺切片，2018-2030 年
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第七章竞争形势

  • 公司分类
  • 策略规划
  • 2022 年公司市场占有率分析
  • 公司简介/名单
    • Intact Medical Corporation.
    • Ethicon Surgical Technologies
    • Gallini SRL
    • Leica Biosystems Nussloch GmbH
    • Hologic, Inc.
    • Argon Medical Devices
    • Encapsule Medical Devices LLC
    • Cook Medical Incorporated
    • Becton, Dickinson and Company
    • CR Bard, Inc.
Product Code: GVR-4-68040-161-0

Breast Cancer Core Needle Biopsy Market Growth & Trends:

The global breast cancer core needle biopsy market is expected to reach USD 1.15 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to grow at a CAGR of 4.9% from 2023 to 2030. The market growth is primarily propelled by factors such as the increasing prevalence of breast cancer, the widespread recommendations for regular mammography screenings, rising awareness among individuals, and extensive research studies conducted in this field. These factors collectively contribute to the rising demand and adoption of breast cancer core needle biopsy procedures, paving the way for significant growth in the coming years.

Additionally, continuous advancements in imaging technologies and biopsy techniques contribute to the expansion of the industry. There is a growing recognition of the crucial role that early detection and diagnosis play in improving patient outcomes. Core needle biopsies offer distinct advantages over traditional open surgical biopsies, including reduced invasiveness, quicker recovery time, and cost-effectiveness.

As the demand for early detection and diagnosis continues to rise, the market for breast cancer core needle biopsy is expected to witness significant growth. A recent example of innovative research in this field involves the use of contrast-mammography-guided breast biopsies that utilize MRI technology for lesion visualization, as demonstrated by researchers at the IMIM (Hospital del Mar Medical Research Institute) in Spain, in 2022 with the findings published in the journal European Radiology.

The COVID-19 pandemic has both challenged and opened new opportunities in the breast cancer core needle biopsy market. Delays in non-essential procedures have led to a decrease in diagnosis rate and demand for core needle biopsies. However, the pandemic has emphasized the importance of early detection, leading healthcare providers to prioritize screenings and biopsies, resulting in a resurgence in demand.

Breast Cancer Core Needle Biopsy Market Report Highlights:

  • By technology, the ultrasound-based breast biopsy segment dominated the market in 2022 due to its advantages over other biopsy technologies in terms of disease diagnosis. Further, increasing technological advancements are also expected to accelerate segment growth.
  • By end-use, hospitals & diagnostic laboratories segment held the largest market share in 2022, due to the increasing adoption of breast cancer biopsy instruments in hospitals along with growing demand for novel diagnostics technologies.
  • North America held a strong regional position in the market in 2022 owing to its highly developed healthcare infrastructure and presence of technologically advanced companies.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Segment Definitions
      • 1.1.1.1. Technology Segment
      • 1.1.1.2. End Use
  • 1.2. Regional Scope
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Objective
    • 1.4.1. Objective 1
    • 1.4.2. Objective 2
    • 1.4.3. Objective 3
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary Research
  • 1.7. Information or Data Analysis:
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
  • 1.10. List of Secondary Sources
  • 1.11. List of Abbreviations

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Trends and Outlook
  • 3.4. Market Drivers
    • 3.4.1. Growing prevalence of breast cancer
    • 3.4.2. Advancement in imaging technologies and biopsy techniques
    • 3.4.3. Rising inclination towards minimally invasive procedures
  • 3.5. Market Restraint
    • 3.5.1. High cost of core needle biopsy procedures
    • 3.5.2. Limited expertise and training
  • 3.6. Industry Analysis Tools
    • 3.6.1. Porter's Five Forces Analysis
    • 3.6.2. PESTEL Analysis
    • 3.6.3. COVID-19 Impact Analysis

Chapter 4. Technology Business Analysis

  • 4.1. Breast Cancer Core Needle Biopsy Market: Technology Movement Analysis
  • 4.2. MRI-Based Breast Biopsy
    • 4.2.1. MRI-Based Breast Biopsy Market, 2018 - 2030 (USD Million)
  • 4.3. Fermentation Ultrasound-Based Breast Biopsy
    • 4.3.1. Ultrasound-Based Breast Biopsy Market, 2018 - 2030 (USD Million)
  • 4.4. Mammography-Based (Stereotactic) Breast Biopsy
    • 4.4.1. Mammography-Based (Stereotactic) Breast Biopsy Market, 2018 - 2030 (USD Million)
  • 4.5. CT-Based Breast Biopsy
    • 4.5.1. CT-Based Breast Biopsy Market, 2018 - 2030 (USD Million)
  • 4.6. Other Image-Based Breast Biopsy
    • 4.6.1. Other Image-Based Breast Biopsy Market, 2018 - 2030 (USD Million)

Chapter 5. End-use Business Analysis

  • 5.1. Breast Cancer Core Needle Biopsy Market: End-use Movement Analysis
  • 5.2. Hospitals & Diagnostic Laboratories
    • 5.2.1. Hospitals & Diagnostic Laboratories Market, 2018 - 2030 (USD Million)
  • 5.3. Pharmaceutical & Biotechnology companies
    • 5.3.1. Pharmaceutical & Biotechnology Companies, Market, 2018 - 2030 (USD Million)
  • 5.4. Academic & Research Institutes
    • 5.4.1. Academic And Research Institutes Market, 2018 - 2030 (USD Million)

Chapter 6. Regional Business Analysis

  • 6.1. Breast Cancer Core Needle Biopsy Market Share By Region, 2022 & 2030
  • 6.2. North America
    • 6.2.1. SWOT Analysis
    • 6.2.2. North America Breast Cancer Core Needle Biopsy, 2018 - 2030 (USD Million)
    • 6.2.3. U.S.
      • 6.2.3.1. Key Country Dynamics
      • 6.2.3.2. Target Disease Prevalence
      • 6.2.3.3. Competitive Scenario
      • 6.2.3.4. Regulatory Framework
      • 6.2.3.5. U.S. Breast Cancer Core Needle Biopsy, 2018 - 2030 (USD Million)
    • 6.2.4. Canada
      • 6.2.4.1. Key Country Dynamics
      • 6.2.4.2. Target Disease Prevalence
      • 6.2.4.3. Competitive Scenario
      • 6.2.4.4. Regulatory Framework
      • 6.2.4.5. Canada Breast Cancer Core Needle Biopsy Market, 2018 - 2030 (USD Million)
  • 6.3. Europe
    • 6.3.1. SWOT Analysis
    • 6.3.2. Europe Breast Cancer Core Needle Biopsy Market, 2018 - 2030 (USD Million)
    • 6.3.3. UK
      • 6.3.3.1. Key Country Dynamics
      • 6.3.3.2. Target Disease Prevalence
      • 6.3.3.3. Competitive Scenario
      • 6.3.3.4. Regulatory Framework
      • 6.3.3.5. UK Breast Cancer Core Needle Biopsy Market, 2018 - 2030 (USD Million)
    • 6.3.4. Germany
      • 6.3.4.1. Key Country Dynamics
      • 6.3.4.2. Target Disease Prevalence
      • 6.3.4.3. Competitive Scenario
      • 6.3.4.4. Regulatory Framework
      • 6.3.4.5. Germany Breast Cancer Core Needle Biopsy Market, 2018 - 2030 (USD Million)
    • 6.3.5. France
      • 6.3.5.1. Key Country Dynamics
      • 6.3.5.2. Target Disease Prevalence
      • 6.3.5.3. Competitive Scenario
      • 6.3.5.4. Regulatory Framework
      • 6.3.5.5. France Breast Cancer Core Needle Biopsy, 2018 - 2030 (USD Million)
    • 6.3.6. Italy
      • 6.3.6.1. Key Country Dynamics
      • 6.3.6.2. Target Disease Prevalence
      • 6.3.6.3. Competitive Scenario
      • 6.3.6.4. Regulatory Framework
      • 6.3.6.5. Italy Breast Cancer Core Needle Biopsy, 2018 - 2030 (USD Million)
    • 6.3.7. Spain
      • 6.3.7.1. Key Country Dynamics
      • 6.3.7.2. Target Disease Prevalence
      • 6.3.7.3. Competitive Scenario
      • 6.3.7.4. Regulatory Framework
      • 6.3.7.5. Spain Breast Cancer Core Needle Biopsy, 2018 - 2030 (USD Million)
    • 6.3.8. Denmark
      • 6.3.8.1. Key Country Dynamics
      • 6.3.8.2. Target Disease Prevalence
      • 6.3.8.3. Competitive Scenario
      • 6.3.8.4. Regulatory Framework
      • 6.3.8.5. Denmark Breast Cancer Core Needle Biopsy, 2018 - 2030 (USD Million)
    • 6.3.9. Sweden
      • 6.3.9.1. Key Country Dynamics
      • 6.3.9.2. Target Disease Prevalence
      • 6.3.9.3. Competitive Scenario
      • 6.3.9.4. Regulatory Framework
      • 6.3.9.5. Sweden Breast Cancer Core Needle Biopsy, 2018 - 2030 (USD Million)
    • 6.3.10. Norway
      • 6.3.10.1. Key Country Dynamics
      • 6.3.10.2. Target Disease Prevalence
      • 6.3.10.3. Competitive Scenario
      • 6.3.10.4. Regulatory Framework
      • 6.3.10.5. Norway Breast Cancer Core Needle Biopsy, 2018 - 2030 (USD Million)
  • 6.4. Asia Pacific
    • 6.4.1. SWOT Analysis
    • 6.4.2. Asia Pacific Breast Cancer Core Needle Biopsy, 2018 - 2030 (USD Million)
    • 6.4.3. Japan
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Target Disease Prevalence
      • 6.4.3.3. Competitive Scenario
      • 6.4.3.4. Regulatory Framework
      • 6.4.3.5. Japan Breast Cancer Core Needle Biopsy, 2018 - 2030 (USD Million)
    • 6.4.4. China
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Target Disease Prevalence
      • 6.4.4.3. Competitive Scenario
      • 6.4.4.4. Regulatory Framework
      • 6.4.4.5. China Breast Cancer Core Needle Biopsy, 2018 - 2030 (USD Million)
    • 6.4.5. India
      • 6.4.5.1. Key Country Dynamics
      • 6.4.5.2. Target Disease Prevalence
      • 6.4.5.3. Competitive Scenario
      • 6.4.5.4. Regulatory Framework
      • 6.4.5.5. India Breast Cancer Core Needle Biopsy, 2018 - 2030 (USD Million)
    • 6.4.6. Australia
      • 6.4.6.1. Key Country Dynamics
      • 6.4.6.2. Target Disease Prevalence
      • 6.4.6.3. Competitive Scenario
      • 6.4.6.4. Regulatory Framework
      • 6.4.6.5. Australia Breast Cancer Core Needle Biopsy, 2018 - 2030 (USD Million)
    • 6.4.7. Thailand
      • 6.4.7.1. Key Country Dynamics
      • 6.4.7.2. Target Disease Prevalence
      • 6.4.7.3. Competitive Scenario
      • 6.4.7.4. Regulatory Framework
      • 6.4.7.5. Thailand Breast Cancer Core Needle Biopsy, 2018 - 2030 (USD Million)
    • 6.4.8. South Korea
      • 6.4.8.1. Key Country Dynamics
      • 6.4.8.2. Target Disease Prevalence
      • 6.4.8.3. Competitive Scenario
      • 6.4.8.4. Regulatory Framework
      • 6.4.8.5. South Korea Breast Cancer Core Needle Biopsy, 2018 - 2030 (USD Million)
  • 6.5. Latin America
    • 6.5.1. SWOT Analysis
    • 6.5.2. Latin America Breast Cancer Core Needle Biopsy, 2018 - 2030 (USD Million)
    • 6.5.3. Brazil
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Target Disease Prevalence
      • 6.5.3.3. Competitive Scenario
      • 6.5.3.4. Regulatory Framework
      • 6.5.3.5. Brazil Breast Cancer Core Needle Biopsy, 2018 - 2030 (USD Million)
    • 6.5.4. Mexico
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Target Disease Prevalence
      • 6.5.4.3. Competitive Scenario
      • 6.5.4.4. Regulatory Framework
      • 6.5.4.5. Mexico Breast Cancer Core Needle Biopsy, 2018 - 2030 (USD Million)
    • 6.5.5. Argentina
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Target Disease Prevalence
      • 6.5.5.3. Competitive Scenario
      • 6.5.5.4. Regulatory Framework
      • 6.5.5.5. Argentina Breast Cancer Core Needle Biopsy, 2018 - 2030 (USD Million)
  • 6.6. MEA
    • 6.6.1. SWOT Analysis
    • 6.6.2. MEA Breast Cancer Core Needle Biopsy, 2018 - 2030 (USD Million)
    • 6.6.3. South Africa
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Target Disease Prevalence
      • 6.6.3.3. Competitive Scenario
      • 6.6.3.4. Regulatory Framework
      • 6.6.3.5. South Africa Breast Cancer Core Needle Biopsy, 2018 - 2030 (USD Million)
    • 6.6.4. Saudi Arabia
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Target Disease Prevalence
      • 6.6.4.3. Competitive Scenario
      • 6.6.4.4. Regulatory Framework
      • 6.6.4.5. Saudi Arabia Breast Cancer Core Needle Biopsy, 2018 - 2030 (USD Million)
    • 6.6.5. UAE
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Target Disease Prevalence
      • 6.6.5.3. Competitive Scenario
      • 6.6.5.4. Regulatory Framework
      • 6.6.5.5. UAE Breast Cancer Core Needle Biopsy, 2018 - 2030 (USD Million)
    • 6.6.6. Kuwait
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Target Disease Prevalence
      • 6.6.6.3. Competitive Scenario
      • 6.6.6.4. Regulatory Framework
      • 6.6.6.5. Kuwait Breast Cancer Core Needle Biopsy, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Company Categorization
  • 7.2. Strategy Mapping
  • 7.3. Company Market Share Analysis, 2022
  • 7.4. Company Profiles/Listing
    • 7.4.1. Intact Medical Corporation.
      • 7.4.1.1. Overview
      • 7.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.1.3. Product Benchmarking
      • 7.4.1.4. Strategic Initiatives
    • 7.4.2. Ethicon Surgical Technologies
      • 7.4.2.1. Overview
      • 7.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.2.3. Product Benchmarking
      • 7.4.2.4. Strategic Initiatives
    • 7.4.3. Gallini SRL
      • 7.4.3.1. Overview
      • 7.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.3.3. Product Benchmarking
      • 7.4.3.4. Strategic Initiatives
    • 7.4.4. Leica Biosystems Nussloch GmbH
      • 7.4.4.1. Overview
      • 7.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.4.3. Product Benchmarking
      • 7.4.4.4. Strategic Initiatives
    • 7.4.5. Hologic, Inc.
      • 7.4.5.1. Overview
      • 7.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.5.3. Product Benchmarking
      • 7.4.5.4. Strategic Initiatives
    • 7.4.6. Argon Medical Devices
      • 7.4.6.1. Overview
      • 7.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.6.3. Product Benchmarking
      • 7.4.6.4. Strategic Initiatives
    • 7.4.7. Encapsule Medical Devices LLC
      • 7.4.7.1. Overview
      • 7.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.7.3. Product Benchmarking
      • 7.4.7.4. Strategic Initiatives
    • 7.4.8. Cook Medical Incorporated
      • 7.4.8.1. Overview
      • 7.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.8.3. Product Benchmarking
      • 7.4.8.4. Strategic Initiatives
    • 7.4.9. Becton, Dickinson and Company
      • 7.4.9.1. Overview
      • 7.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.9.3. Product Benchmarking
      • 7.4.9.4. Strategic Initiatives
    • 7.4.10. C.R. Bard, Inc.
      • 7.4.10.1. Overview
      • 7.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.10.3. Product Benchmarking
      • 7.4.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 Global breast cancer core needle biopsy market, by technology, 2018 - 2030 (USD Million)
  • Table 3 Global breast cancer core needle biopsy market, by end-use, 2018 - 2030 (USD Million)
  • Table 4 Global breast cancer core needle biopsy market, by region, 2018 - 2030 (USD Million)
  • Table 5 North America breast cancer core needle biopsy market, by country, 2018 - 2030 (USD Million)
  • Table 6 North America breast cancer core needle biopsy market, by technology, 2018 - 2030 (USD Million)
  • Table 7 North America breast cancer core needle biopsy market, by end-use, 2018 - 2030 (USD Million)
  • Table 8 U.S. breast cancer core needle biopsy market, by technology, 2018 - 2030 (USD Million)
  • Table 9 U.S. breast cancer core needle biopsy market, by end-use, 2018 - 2030 (USD Million)
  • Table 10 Canada breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 11 Canada breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 12 Europe breast cancer core needle biopsy, by country, 2018 - 2030 (USD Million)
  • Table 13 Europe breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 14 Europe breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 15 UK breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 16 UK breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 17 Germany breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 18 Germany breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 19 France breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 20 France breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 21 Italy breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 22 Italy breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 23 Spain breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 24 Spain breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 25 Denmark breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 26 Denmark breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 27 Sweden breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 28 Sweden breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 29 Norway breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 30 Norway breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 31 Asia Pacific breast cancer core needle biopsy, by country, 2018 - 2030 (USD Million)
  • Table 32 Asia Pacific breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 33 Asia Pacific breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 34 Japan breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 35 Japan breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 36 China breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 37 China breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 38 India breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 39 India breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 40 Australia breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 41 Australia breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 42 Thailand breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 43 Thailand breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 44 South Korea breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 45 South Korea breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 46 Latin America breast cancer core needle biopsy, by country, 2018 - 2030 (USD Million)
  • Table 47 Latin America breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 48 Latin America breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 49 Brazil breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 50 Brazil breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 51 Mexico breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 52 Mexico breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 53 Argentina breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 54 Argentina breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 55 Middle East & Africa breast cancer core needle biopsy, by country, 2018 - 2030 (USD Million)
  • Table 56 Middle East & Africa breast cancer core needle biopsy, by technology, 2018-2030, (USD
  • Table 57 Middle East & Africa breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 58 South Africa breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 59 South Africa breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 60 Saudi Arabia breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 61 Saudi Arabia breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 62 UAE breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 63 UAE breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 64 Kuwait breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 65 Kuwait breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value chain-based sizing & forecasting
  • Fig. 6 Market formulation & validation
  • Fig. 7 breast cancer core needle biopsy market segmentation
  • Fig. 8 Market snapshot, 2022
  • Fig. 9 Market trends & outlook
  • Fig. 10 Market driver relevance analysis (current & future impact)
  • Fig. 11 Market restraint relevance analysis (current & future impact)
  • Fig. 12 SWOT analysis, by factor (political & legal, economic, and technological)
  • Fig. 13 Porter's Five Forces analysis
  • Fig. 14 Market penetration & growth prospect mapping, 2022
  • Fig. 15 Global breast cancer core needle biopsy market: Technology movement analysis
  • Fig. 16 Global breast cancer core needle biopsy market, for MRI-based breast biopsy, 2018 - 2030 (USD Million)
  • Fig. 17 Global breast cancer core needle biopsy market, for ultrasound-based breast biopsy, 2018 - 2030 (USD Million)
  • Fig. 18 Global breast cancer core needle biopsy market, for mammography-based (stereotactic) breast biopsy, 2018 - 2030 (USD Million)
  • Fig. 19 Global breast cancer core needle biopsy market, for CT-based breast biopsy, 2018 - 2030 (USD Million)
  • Fig. 20 Global breast cancer core needle biopsy market, for other image-based breast biopsy, 2018 - 2030 (USD Million)
  • Fig. 21 Global breast cancer core needle biopsy market: End use movement analysis
  • Fig. 22 Global breast cancer core needle biopsy market, for hospitals & diagnostic laboratories, 2018 - 2030 (USD Million)
  • Fig. 23 Global breast cancer core needle biopsy market, for pharmaceutical & biotechnology companies, 2018 - 2030 (USD Million)
  • Fig. 24 Global breast cancer core needle biopsy market, for academic & research institutes, 2018 - 2030 (USD Million)
  • Fig. 25 Regional marketplace: Key takeaways
  • Fig. 26 Regional outlook, 2022 & 2030
  • Fig. 27 Global breast cancer core needle biopsy market: Region movement analysis
  • Fig. 28 North America breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 29 U.S. breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 30 Canada breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 31 Europe breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 32 Germany breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 33 UK breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 34 France breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 35 Italy breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 36 Spain breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 37 Denmark breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 38 Sweden breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 39 Norway breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 40 Asia Pacific breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 41 Japan breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 42 China breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 43 India breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 44 Australia breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 45 South Korea breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 46 Thailand breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 47 Latin America breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 48 Brazil breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 49 Mexico breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 50 Argentina breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 51 Middle East and Africa breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 52 South Africa breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 53 Saudi Arabia breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 54 UAE breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 55 Kuwait breast cancer core needle biopsy market, 2018 - 2030 (USD Million)